A methylone drug eased PTSD in phase 2, without MDMA trials' long therapy sessions

Most rapid-acting psychedelic and psychedelic-adjacent PTSD trials pair the drug with structured psychotherapy delivered over many hours per dosing session, a resource-intensive model that has raised questions about how such treatments could scale. A phase 2 trial published this week in JAMA Psychiatry tests a different approach: TSND-201, an oral formulation of methylone, given without formal psychotherapy [s1].

What TSND-201 is

TSND-201 is methylone, described by the trial's authors as "a highly selective, rapid-acting neuroplastogen" that releases serotonin, norepinephrine, and dopamine without directly activating the 5-HT2A serotonin receptor — the receptor classic psychedelics like psilocybin and LSD act on to produce their perception-altering effects [s1]. That distinction is central to the drug's proposed appeal: it's designed to trigger rapid, lasting neurobiological change associated with symptom relief without producing a classic hallucinogenic experience, and the trial notes it had already shown benefit for PTSD-related behaviors in animal studies and had been well tolerated in phase 1 healthy-volunteer studies before this trial [s1].

The design

IMPACT-1 Part B was a phase 2, multicenter, double-blind, placebo-controlled, 10-week trial conducted between November 2023 and February 2025 across 16 sites in the US, UK, and Ireland [s1]. Eligible adults, aged 18 to 65, met DSM-5 criteria for current PTSD with at least six months of symptoms and a baseline CAPS-5 score (a clinician-administered PTSD severity scale) of 35 or higher [s1]. Participants were randomized 1:1 to TSND-201 or placebo, receiving four once-weekly oral dosing sessions — 150 mg followed by 100 mg, or matched placebo [s1]. No formal psychotherapy was provided; dosing sessions were monitored by mental health professionals using a nondirective approach, and participants were followed for six weeks after the final dose [s1].

What it found

Among 65 participants (mean age 43.7, 60% female), TSND-201 produced significantly greater improvement in CAPS-5 total severity score than placebo, with a least-squares mean treatment difference of 9.64 points (90% CI −16.48 to −2.80, p = .01) [s1]. Secondary measures also favored TSND-201: the PTSD Checklist for DSM-5 improved by 8.99 points more than placebo (90% CI −17.81 to −0.17), the Sheehan Disability Scale by 4.72 points more (90% CI −8.84 to −0.61), and the Montgomery-Åsberg Depression Rating Scale by 6.21 points more (90% CI −12.41 to −0.27) [s1]. Common treatment-emergent adverse events with TSND-201 included headache, decreased appetite, nausea, dizziness, increased blood pressure, dry mouth, and insomnia [s1].

Reading the confidence intervals

Note that these confidence intervals are reported at 90%, not the more conventional 95% — a choice the trial specifies but doesn't explain in the available abstract, and one that produces narrower intervals than a 95% CI would for the same data, which is a detail worth flagging when comparing this trial's precision against others that report 95% intervals by default. The primary CAPS-5 result's 90% CI still excludes zero (−16.48 to −2.80), meaning the finding clears that specific statistical bar, but readers should note the intervals aren't directly comparable to trials using the more standard 95% threshold without adjustment.

Why the lack of formal psychotherapy is the story's real hook

MDMA-assisted therapy for PTSD, the furthest-along comparable treatment in development, has built its entire protocol around extended, structured psychotherapy sessions accompanying each dose — a model widely seen as central to both its efficacy and its cost and scalability challenges. TSND-201's trial design, offering monitored but non-directive support rather than formal psychotherapy, tests whether a methylone-based drug can produce meaningful PTSD symptom relief without that resource-intensive therapeutic scaffolding [s1]. If that pattern holds in larger trials, it would represent a materially different, potentially more scalable treatment model than the MDMA-assisted-therapy approach — though this single 65-person trial doesn't establish that on its own, and doesn't include a head-to-head comparison against therapy-paired approaches.

What this doesn't establish

This is a phase 2 trial in 65 participants — a real but still early-stage dataset, not sufficient on its own to support regulatory approval. The wide confidence intervals across all endpoints reflect the sample size and leave meaningful uncertainty about the true effect size. Long-term durability beyond the six-week post-dose follow-up window is not addressed by this trial's data as summarized. TSND-201 is not approved by any regulator.

What to watch

Whether a phase 3 program is launched and whether it replicates this signal at larger scale, and how the drug's non-psychotherapy-paired model compares against psychotherapy-integrated approaches in head-to-head or cross-trial analysis. This article describes investigational drug trial results; it is not medical advice.

Sources

1. Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial — JAMA Psychiatry, 1 May 2026